<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278822</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000405</org_study_id>
    <nct_id>NCT02278822</nct_id>
  </id_info>
  <brief_title>Oral Liposomal Glutathione Supplementation in Healthy Subjects</brief_title>
  <official_title>Pilot Study of Oral Liposomal Glutathione Supplementation on Levels of Glutathione in Blood and Biomarkers of Oxidative Stress and Immune Function in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to provide evidence of the efficacy of liposomal glutathione
      supplementation on healthy adults. The investigators anticipate that liposomal glutathione
      supplementation will enhance the levels of blood glutathione and improve the immune
      functions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized study on healthy individuals. The study design includes the recruitment
      of 12 healthy male and female subjects (50-80 yr of age) randomized into 2 groups of 6 each
      (liposomal glutathione at 500 mg/day or liposomal glutathione at 1000 mg/day). Blood and
      urine samples will be obtained from all subjects at baseline. Eligible subjects will be
      required to have not have taken any high dose antioxidant supplements for at least 1 month
      prior to the study. Subjects will then begin supplementation according to the following
      schedule: Group A, liposomal glutathione (500 mg daily), Group B, liposomal glutathione (1000
      mg daily)

      Eligible participants who sign the informed consent will be randomly assigned to either low
      dose or high dose glutathione groups. Participants will be asked not to consume any other
      high-dose vitamin, multi-vitamin, or mineral supplements containing glutathione throughout
      the study in order to prevent variation in dose of supplemental liposomal glutathione between
      subjects. Participants are to limit their consumption of alcohol in the study to no more than
      5 oz. of alcohol per week. Supplementation will continue for 1 month with biological samples
      collected at 1, 2 and 4 weeks after baseline.

      Levels of glutathione will be measured in whole blood, erythrocytes, lymphocytes and plasma.
      The biomarkers of oxidative stress will include urinary 8-isoprostane and urinary
      8-hydroxydeoxyguanosine. Immune function biomarkers will be analyzed including lymphocyte
      proliferation and natural killer (NK) cell cytotoxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glutathione levels in blood</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure immune function biomarkers in blood</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Low dose oral liposomal glutathione</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: low dose oral liposomal glutathione supplementation. 500 mg oral liposomal glutathione each day for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose oral liposomal glutathione</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: high dose oral liposomal glutathione supplementation. 1000 mg oral liposomal glutathione each day for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low dose oral liposomal glutathione supplementation</intervention_name>
    <description>Low dose oral liposomal glutathione supplementation</description>
    <arm_group_label>Low dose oral liposomal glutathione</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High dose oral liposomal glutathione supplementation</intervention_name>
    <description>High dose oral liposomal glutathione supplementation</description>
    <arm_group_label>High dose oral liposomal glutathione</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy English-speaking male and female volunteers

          -  Baseline blood glutathione level of â‰¤ 0.9 mmol/l

          -  Non-smoking individuals

        Exclusion Criteria:

          -  No history or evidence of disease including cancer, diabetes, heart disease.

          -  Not taking glutathione as a dietary supplement

          -  Not taking high-dose antioxidant supplements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raghu Sinha, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M.S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <last_update_submitted>July 7, 2016</last_update_submitted>
  <last_update_submitted_qc>July 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Raghu Sinha</investigator_full_name>
    <investigator_title>Associate Professor of Biochemistry and Molecular Biology</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

